Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Mixture
Record UNII
6D53G0FD0Z
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
PLASMA PROTEIN FRACTION (HUMAN)
WHO-DD  
Common Name
English  
PLASMA, PROTEIN FRACTION (HUMAN)
Common Name
English  
PLASMA PROTEIN FRACTION,HUMAN [VANDF]
Common Name
English  
PLASMA PROTEIN FRACTION HUMAN
Common Name
English  
PLASMA PROTEIN FRACTION (HUMAN) [WHO-DD]
Common Name
English  
Classification Tree Code System Code Access References
CFR 21 CFR 640.90
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
CFR 21 CFR 640.91
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
CFR 21 CFR 640.92
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
CFR 21 CFR 640.93
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
CFR 21 CFR 640.94
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
Code System Code Type Description Access References
EVMPD
SUB127871
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
PRIMARY
DRUG BANK
DB13968
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
PRIMARY
FDA UNII
6D53G0FD0Z
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
PRIMARY
RXCUI
33835
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
PRIMARY RxNorm
All of the following components must be present:
Related Record Type Details Access References
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
GLE is approximately 97.5% bound to human plasma proteins independent of concentration from 0.1 to 30 ?M (800 to 25,200 ng/mL).
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to ?1-acid glycoprotein.
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
with no concentration dependence over the range of 100–500 ng/mL
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Protein binding of tepotinib is 98% and is independent of drug concentration at clinically relevant exposures.
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
In vitro plasma protein binding of lonafarnib was greater than or equal to 99% over the concentration range between 0.5 to 40.0 ?g/mL.
Created by admin on Wed Aug 04 03:47:16 EDT 2021 , Edited by admin on Wed Aug 04 03:47:16 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Ivacaftor is approximately 99% bound to plasma proteins, primarily to albumin, and also to alpha 1-acid glycoprotein and human gamma-globulin.
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Glasdegib is 91% bound to human plasma proteins in vitro
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
The percentages ixabepilone bound to proteins at concentrations of 50, 500 and 5000 ng/mL were 76.6%, 72.0% and 67.1%, respectively. The protein binding of ixabepilone was not concentration dependent from 50 ng/mL to 5000 ng/mL.
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
primarily to alpha-1-acid glycoprotein.
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Human plasma protein binding of pretomanid is approximately 86.4% and is independent of drug concentration.
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
in vivo
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
tezacaftor are approximately 99% bound to plasma proteins, primarily to albumin.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Plasma protein binding is independent on nelarabine concentrations.
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
The bound concentration increased slightly (,2%) as the concentration of 14C-rifapentine increased from 0.5 to 10 mg/ml. At concentrations above 10 mg/ml, protein binding did not appear to vary with increasing concentration.
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
For M16, protein binding was moderate and ranged from 82.6 to 85.7% 0.5 hr after avanafil administration.
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Reported not to bind to serum proteins
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
BINDER->LIGAND
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ? 98% in healthy subjects and in subjects with renal or hepatic impairment.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Encorafenib is 86% bound to human plasma proteins and binding is not concentrationdependent
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Abametapir plasm protein binding ranged from 91.3 – 92.3% and was concentration independent within the tested concentration range of 50 – 800 ng/mL.
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Miglustat does not bind to plasma proteins.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:14 EDT 2021 , Edited by admin on Wed Aug 04 03:47:14 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Binding to human plasma proteins was low (approximately 22 %) and independent of the concentration of zoledronic acid.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:16 EDT 2021 , Edited by admin on Wed Aug 04 03:47:16 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:04 EDT 2021 , Edited by admin on Wed Aug 04 03:47:04 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:07 EDT 2021 , Edited by admin on Wed Aug 04 03:47:07 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:16 EDT 2021 , Edited by admin on Wed Aug 04 03:47:16 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Protein binding of lemborexant is approximately 93.2% to 94.0% between 29 ng/mL and 71 ng/mL.
Created by admin on Wed Aug 04 03:47:15 EDT 2021 , Edited by admin on Wed Aug 04 03:47:15 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:11 EDT 2021 , Edited by admin on Wed Aug 04 03:47:11 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:06 EDT 2021 , Edited by admin on Wed Aug 04 03:47:06 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
The in vitro protein binding in human plasma is below 8% for tipiracil.
Created by admin on Wed Aug 04 03:47:13 EDT 2021 , Edited by admin on Wed Aug 04 03:47:13 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:03 EDT 2021 , Edited by admin on Wed Aug 04 03:47:03 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:08 EDT 2021 , Edited by admin on Wed Aug 04 03:47:08 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:02 EDT 2021 , Edited by admin on Wed Aug 04 03:47:02 EDT 2021
LIGAND->BINDER
Mediator Substance Details
none
BINDING
Created by admin on Wed Aug 04 03:47:12 EDT 2021 , Edited by admin on Wed Aug 04 03:47:12 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:05 EDT 2021 , Edited by admin on Wed Aug 04 03:47:05 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:01 EDT 2021 , Edited by admin on Wed Aug 04 03:47:01 EDT 2021
LIGAND->BINDER
none
Mediator Substance Details
none
BINDING
~90% Gilteritinib bound to plasma proteins, mainly albumin
Created by admin on Wed Aug 04 03:47:09 EDT 2021 , Edited by admin on Wed Aug 04 03:47:09 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:10 EDT 2021 , Edited by admin on Wed Aug 04 03:47:10 EDT 2021
LIGAND->BINDER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:47:00 EDT 2021 , Edited by admin on Wed Aug 04 03:47:00 EDT 2021
SUB_CONCEPT->SUBSTANCE
none